Intervention not reported
- Ambulatory oxygen for people with chronic obstructive pulmonary disease who are not hypoxaemic at rest 2014 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Systemic corticosteroid leads to lower treatment failure Need to intensify therapy/ED or hospital admission compared with placebo (high certainty).
Treatment route: intravenous corticosteroid showed no clear difference in mortality after discharge (1‐3 months) compared with oral corticosteroid (moderate certainty).
Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).
Systemic corticosteroid showed no clear difference in relapse Treatment for AE of COPD or hospital re‐admission compared with placebo (moderate certainty).
Systemic corticosteroid leads to higher adverse drug effect compared with placebo (high certainty).
Systemic corticosteroid leads to higher hyperglycaemia compared with placebo (high certainty).
Treatment route: intravenous corticosteroid showed no clear difference in treatment failure Need to intensify therapy compared with oral corticosteroid (moderate certainty).
Treatment route: intravenous corticosteroid showed no clear difference in relapse Hospital readmission for COPD compared with oral corticosteroid (moderate certainty).
It is very uncertain whether PEEP changes postoperative mortality compared with zero end‐expiratory pressure (ZEEP) during mechanical ventilation (very low certainty).
It is very uncertain whether PEEP changes pneumonia compared with zero end‐expiratory pressure (ZEEP) during mechanical ventilation (very low certainty).
The review found no eligible studies for this question.